Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The PRECISE European initiative for cancer-vulnerability mapping and prediction.

Nature genetics·2026
Same author

Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.

Cancer research·2026
Same author

Harnessing myeloid cell plasticity for cancer therapy.

Nature cancer·2026
Same author

10 × Genomics Flex Gene Expression is a powerful tool for single-cell transcriptomics of xenografts models.

Genome biology·2026
Same author

Enabling AI to Drive Innovation and Precision across Oncology R&D.

Cancer discovery·2026
Same author

Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Jul 1, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.8K

Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.

Azadeh C Bashi1, Elizabeth A Coker2, Krishna C Bulusu1

  • 1Oncology R&D, AstraZeneca, Cambridge, United Kingdom.

Cancer Discovery
|March 8, 2024
PubMed
Summary
This summary is machine-generated.

This study screened 109 oncology drug combinations across 755 cancer cell lines, identifying three actionable combinations for specific patient populations. This research advances precision oncology by finding novel drug synergies.

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.8K

Related Experiment Videos

Last Updated: Jul 1, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.8K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.8K

Area of Science:

  • Oncology
  • Pharmacology
  • Genomics

Background:

  • Cancer drug combinations offer improved therapeutic responses and expanded treatment options.
  • The vast number of potential combinations and context-specific responses necessitate systematic screening.
  • Identifying clinically relevant combinations in defined patient subtypes is crucial for effective cancer therapy.

Purpose of the Study:

  • To systematically screen 109 anticancer drug combinations from AstraZeneca's portfolio in 755 pan-cancer cell lines.
  • To implement a novel approach using combination effect (Emax) and highest single agent (HSA) to assess combination benefits.
  • To design a clinical translatability workflow for identifying actionable combinations with defined patient populations and biomarkers.

Main Methods:

  • Screening of 109 drug combinations in a 7x7 concentration matrix across 755 pan-cancer cell lines, generating over 4 million viability measurements.
  • Utilizing combination Emax and highest single agent (HSA) for assessing drug synergy and therapeutic benefit.
  • Developing a clinical translatability workflow incorporating patient stratification, tolerability rationale, emergent biomarkers, and clinical dose relevance.

Main Results:

  • Generated a data-rich resource from over 4 million sensitivity measurements for 109 drug combinations.
  • Identified three actionable drug combinations in defined cancer types, including hematologic cancers.
  • Confirmed in vitro and in vivo efficacy of selected combinations, focusing on apoptotic targets and emergent biomarkers.

Conclusions:

  • Systematic screening and a novel assessment approach can identify clinically relevant oncology drug combinations.
  • The developed workflow prioritizes combinations for clinical translatability, enabling precision medicine strategies.
  • Three novel, actionable drug combinations were validated, offering potential new therapeutic options for specific cancer types.